دورية أكاديمية
Emergence of linezolid-resistant Enterococcus faecium in a tertiary hospital in Copenhagen.
| العنوان: | Emergence of linezolid-resistant Enterococcus faecium in a tertiary hospital in Copenhagen. |
|---|---|
| المؤلفون: | Misiakou MA; Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark., Hertz FB; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark., Schønning K; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Häussler S; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.; Twincore, Centre for Experimental and Clinical Infection Research, Hannover, Germany., Nielsen KL; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark. |
| المصدر: | Microbial genomics [Microb Genom] 2023 Jul; Vol. 9 (7). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Microbiology Society Country of Publication: England NLM ID: 101671820 Publication Model: Print Cited Medium: Internet ISSN: 2057-5858 (Electronic) Linking ISSN: 20575858 NLM ISO Abbreviation: Microb Genom Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oct. 2015- : [London] : Microbiology Society Original Publication: [London] : Society for General Microbiology, [2015]- |
| مواضيع طبية MeSH: | Enterococcus faecium*/genetics , Vancomycin-Resistant Enterococci*/genetics, Humans ; Linezolid/pharmacology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Vancomycin/pharmacology ; Vancomycin/therapeutic use ; Tertiary Care Centers ; Multilocus Sequence Typing |
| مستخلص: | Linezolid is used as first-line treatment of infections caused by vancomycin-resistant Enterococcus faecium . However, resistance to linezolid is increasingly detected. The aim of the present study was to elucidate the causes and mechanisms for the increase in linezolid-resistant E. faecium at Copenhagen University Hospital - Rigshospitalet. We therefore combined patient information on linezolid treatment with whole-genome sequencing data for vancomycin- or linezolid-resistant E. faecium isolates that had been systematically collected since 2014 ( n =458). Whole-genome sequencing was performed for multilocus sequence typing (MLST), identification of linezolid resistance-conferring genes/mutations and determination of phylogenetically closely related strains. The collection of E. faecium isolates belonged to prevalent vancomycin-resistant MLST types. Among these, we identified clusters of closely related linezolid-resistant strains compatible with nosocomial transmission. We also identified linezolid-resistant enterococcus isolates not genetically closely related to other isolates compatible with de novo generation of linezolid resistance. Patients with the latter isolates were significantly more frequently exposed to linezolid treatment than patients with related linezolid-resistant enterococcus isolates. We also identified six patients who initially carried a vancomycin-resistant, linezolid-sensitive enterococcus, but from whom vancomycin-resistant, linezolid-resistant enterococci (LVRE) closely related to their initial isolate were recovered after linezolid treatment. Our data illustrate that linezolid resistance may develop in the individual patient subsequent to linezolid exposure and can be transmitted between patients in a hospital setting. |
| References: | Euro Surveill. 2019 Aug;24(34):. (PMID: 31456560) J Antimicrob Chemother. 2017 Feb;72(2):354-364. (PMID: 27999068) Diagn Microbiol Infect Dis. 2003 Nov;47(3):511-3. (PMID: 14596970) J Antimicrob Chemother. 2021 Aug 12;76(9):2260-2267. (PMID: 34151364) Mol Microbiol. 2005 Aug;57(4):1064-73. (PMID: 16091044) Drugs Today (Barc). 2000 Sep;36(9):631-9. (PMID: 12847568) Eur J Clin Microbiol Infect Dis. 2023 Jan;42(1):67-76. (PMID: 36378364) mBio. 2016 Mar 22;7(2):e01975. (PMID: 27006457) Euro Surveill. 2012 Nov 15;17(46):. (PMID: 23171822) Antimicrob Agents Chemother. 1998 Dec;42(12):3251-5. (PMID: 9835522) Bioinformatics. 2014 May 1;30(9):1312-3. (PMID: 24451623) Int J Med Microbiol. 2021 Feb;311(2):151477. (PMID: 33524636) J Antimicrob Chemother. 2023 Feb 1;78(2):445-449. (PMID: 36509546) Antimicrob Agents Chemother. 2017 Jun 27;61(7):. (PMID: 28483950) Virulence. 2012 Aug 15;3(5):421-33. (PMID: 23076243) Microbiol Spectr. 2018 Jul;6(4):. (PMID: 30051804) J Antimicrob Chemother. 2012 Nov;67(11):2640-4. (PMID: 22782487) Drug Resist Updat. 2018 Sep;40:25-39. (PMID: 30447411) APMIS. 2022 Nov;130(11):657-660. (PMID: 35851968) Microb Drug Resist. 2022 Jan;28(1):73-80. (PMID: 34491861) Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296. (PMID: 33885785) Genome Biol. 2014;15(11):524. (PMID: 25410596) Clin Infect Dis. 2004 Oct 1;39(7):1010-5. (PMID: 15472854) J Antimicrob Chemother. 2018 Jul 1;73(7):1763-1769. (PMID: 29635422) J Antimicrob Chemother. 2021 Jul 15;76(8):1978-1985. (PMID: 33895846) J Antimicrob Chemother. 2017 Dec 01;72(12):3252-3257. (PMID: 28961986) Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):83-90. (PMID: 11305477) Antimicrob Agents Chemother. 2002 Oct;46(10):3334-6. (PMID: 12234875) Expert Rev Anti Infect Ther. 2014 Oct;12(10):1221-36. (PMID: 25199988) PLoS Comput Biol. 2015 Feb 12;11(2):e1004041. (PMID: 25675341) J Antimicrob Chemother. 2019 Jul 1;74(7):1776-1785. (PMID: 30929020) J Antimicrob Chemother. 2016 Jul;71(7):1860-5. (PMID: 27013481) Microorganisms. 2020 Jul 30;8(8):. (PMID: 32751552) |
| فهرسة مساهمة: | Keywords: SNP; VRE; outbreak; oxazolidinone; resistance mutation; selection pressure; whole-genome sequencing |
| المشرفين على المادة: | ISQ9I6J12J (Linezolid) 0 (Anti-Bacterial Agents) 6Q205EH1VU (Vancomycin) |
| تواريخ الأحداث: | Date Created: 20230706 Date Completed: 20230710 Latest Revision: 20231116 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10438815 |
| DOI: | 10.1099/mgen.0.001055 |
| PMID: | 37410656 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2057-5858 |
|---|---|
| DOI: | 10.1099/mgen.0.001055 |